Insmed Incorporated (INSM)

Market Cap	12.60B
Revenue (ttm)	342.96M
Net Income (ttm)	-864.29M
Shares Out	178.90M
EPS (ttm)	-5.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,440,524
Open	68.80
Previous Close	69.41
Day's Range	68.80 - 71.06
52-Week Range	21.92 - 80.53
Beta	1.11
Analysts	Strong Buy
Price Target	84.29 (+19.66%)
Earnings Date	Feb 20, 2025

About INSM

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil P...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 1, 2000
• Employees: 912
• Stock Exchange: NASDAQ
• Ticker Symbol: INSM
• Website: https://www.insmed.com

Financial Performance

In 2023, Insmed's revenue was $305.21 million, an increase of 24.39% compared to the previous year's $245.36 million. Losses were -$749.57 million, 55.7% more than in 2022.

Analyst Forecast

According to 16 analysts, the average rating for INSM stock is "Strong Buy." The 12-month stock price forecast is $84.29, which is an increase of 19.66% from the latest price.

Price Target

$84.29

(19.66% upside)

Analyst Consensus: Strong Buy